FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	9	,		

	OMB APPRO	VAL
	OMB Number:	3235-0287
l	Estimated average burd	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							50(1	1) 01 1110			zompany Act	0. 10-0								
1. Name and Address of Reporting Person* <u>Dilone Enrique</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol AMICUS THERAPEUTICS INC [ FOLD ]									all appli Directo	,		10% O	on(s) to Issuer  10% Owner  Other (specify	
(Last) (First) (Middle) 1 CEDAR BROOK DRIVE					Date of 3/20/20		est Trar	nsaction	(Mon	th/Day/Year)		X	below)	)	Technical Operations		эрсспу			
(Street) CRANBURY NJ 08512				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable ine)  X Form filed by One Reporting Person Form filed by More than One Reporting						
(City) (State) (Zip)						Person														
			le I - N			_				d, D	isposed o			ially						
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/						Execution Date,				s Acquired (A) or f (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) or (D)	Price		Transac (Instr. 3	ction(s)			(11341.4)		
Common stock 03/20/201					015	15		M <sup>(1)</sup>		14,045	A	\$11.5	108(2)	64	64,045		D			
Common srock 03/20/20					015	15		S <sup>(1)</sup>		14,045	D	\$11.5	108(3)	50	50,000		D			
		ד	Table I						•	•	posed of , converti	•		-	wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, //Day/Year)		action (Instr.			6. Date Exercisable and Expiration Date (Month/Day/Year)		ate	7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		De Se (Ir	rivative curity Secstr. 5) Become Folk Registr.	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amou or Numb of Share	ber						
Stock Options (right to buy)	\$4.16	03/20/2015			M <sup>(1)</sup>			3,250	11/01/	2013	11/16/2019	Common Stock	3,25	50	\$0.00	9,750		D		
Stock Options (right to buy)	\$4.38	03/20/2015			M <sup>(1)</sup>			1,896	06/04/	2013	06/04/2022	Common stock	1,89	96	\$0.00	33,104		D		
Stock Options (right to buy)	\$3.53	03/20/2015			M <sup>(1)</sup>			2,624	01/28/	2014	01/28/2023	Common stock	2,62	24	\$0.00	25,376		D		
Stock Options (right to buy)	\$2.52	03/20/2015			M <sup>(1)</sup>			3,463	06/18/	2014	06/18/2023	Common stock	3,46	53	\$0.00	31,537	,	D		
Stock Options (right to	\$2.45	03/20/2015			M <sup>(1)</sup>			2,812	01/03/	2015	01/03/2024	Common stock	2,81	2	\$0.00	42,188		D		

## **Explanation of Responses:**

- 1. The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
- 2. This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from \$11.17 to \$11.90. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- 3. This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from \$11.17 to \$11.90. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

## Remarks:

/s/ Enrique Dilone

03/24/2015

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.